JP2013525290A - Ｋｓｐ阻害剤としてのオキサゾールおよびチアゾール化合物 - Google Patents

Ｋｓｐ阻害剤としてのオキサゾールおよびチアゾール化合物 Download PDF

Info

Publication number
JP2013525290A
JP2013525290A JP2013504270A JP2013504270A JP2013525290A JP 2013525290 A JP2013525290 A JP 2013525290A JP 2013504270 A JP2013504270 A JP 2013504270A JP 2013504270 A JP2013504270 A JP 2013504270A JP 2013525290 A JP2013525290 A JP 2013525290A
Authority
JP
Japan
Prior art keywords
substituted
alkyl
group
compound
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013504270A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013525290A5 (enExample
Inventor
ポール・エイ・バーサンティ
ユ・ディング
ハン・ウソク
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2013525290A publication Critical patent/JP2013525290A/ja
Publication of JP2013525290A5 publication Critical patent/JP2013525290A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2013504270A 2010-04-15 2011-04-13 Ｋｓｐ阻害剤としてのオキサゾールおよびチアゾール化合物 Pending JP2013525290A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32467810P 2010-04-15 2010-04-15
US61/324,678 2010-04-15
PCT/EP2011/055855 WO2011128388A2 (en) 2010-04-15 2011-04-13 Oxazole and thiazole compounds as ksp inhibitors

Publications (2)

Publication Number Publication Date
JP2013525290A true JP2013525290A (ja) 2013-06-20
JP2013525290A5 JP2013525290A5 (enExample) 2014-04-24

Family

ID=43981716

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013504270A Pending JP2013525290A (ja) 2010-04-15 2011-04-13 Ｋｓｐ阻害剤としてのオキサゾールおよびチアゾール化合物

Country Status (5)

Country Link
US (1) US8748626B2 (enExample)
EP (1) EP2558452A2 (enExample)
JP (1) JP2013525290A (enExample)
CN (1) CN103153970A (enExample)
WO (1) WO2011128388A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013523867A (ja) * 2010-04-15 2013-06-17 ノバルティス アーゲー Ｋｓｐ阻害剤としてのトリアゾール化合物

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105451773A (zh) * 2013-03-15 2016-03-30 诺华股份有限公司 细胞增殖抑制剂及其缀合物
CA2937989A1 (en) * 2014-01-29 2015-08-06 Bayer Pharma Aktiengesellschaft Amino-substituted isothiazoles
EP2980088A1 (en) * 2014-07-28 2016-02-03 Bayer Pharma Aktiengesellschaft Amino-substituted isothiazoles
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008502721A (ja) * 2004-05-21 2008-01-31 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 分裂キネシンインヒビターとしての置換キノリン誘導体
JP2008503501A (ja) * 2004-06-18 2008-02-07 カイロン コーポレイション 癌を治療するためのキネシンスピンドルタンパク質（ｋｓｐ）阻害剤としてのｎ−（１−（１−ベンジル−４−フェニル−１ｈ−イミダゾール−２−イル）−２，２−ジメチルプロピル）ベンズアミド誘導体および関連化合物
JP2008517057A (ja) * 2004-10-19 2008-05-22 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド インドールおよびベンゾイミダゾール誘導体
JP2008527038A (ja) * 2005-01-19 2008-07-24 メルク エンド カムパニー インコーポレーテッド 有糸分裂キネシン阻害剤
JP2008535839A (ja) * 2005-04-07 2008-09-04 メルク エンド カムパニー インコーポレーテッド 有糸分裂キネシン阻害剤
WO2009077448A1 (en) * 2007-12-14 2009-06-25 Novartis Ag Kinesin inhibitors as cancer therapeutics
JP2009542658A (ja) * 2006-06-27 2009-12-03 ザ プロクター アンド ギャンブル カンパニー ヒトプロテインチロシンホスファターゼβ阻害剤および使用法
JP2010509365A (ja) * 2006-11-13 2010-03-25 ノバルティス アーゲー Ｋｓｐ阻害剤としての置換ピラゾールおよびトリアゾール化合物
JP2013523867A (ja) * 2010-04-15 2013-06-17 ノバルティス アーゲー Ｋｓｐ阻害剤としてのトリアゾール化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
NO318318B1 (no) * 2003-06-27 2005-02-28 Tandberg Telecom As Fremgangsmate for forbedret koding av video
AU2008205169B2 (en) * 2007-01-05 2012-02-02 Novartis Ag Imidazole derivatives as kinesin spindle protein inhibitors (Eg-5)
CN101687852A (zh) * 2007-05-24 2010-03-31 沃泰克斯药物股份有限公司 可用作激酶抑制剂的噻唑类和吡唑类化合物
CL2008003063A1 (es) * 2007-10-19 2010-01-04 Schering Corp Compuestos derivados de 1,3,4-tiadiazol espiro condensado, inhibidores de la actividad quinesina ksp; composicion farmaceutica; y su uso en el tratamiento de enfermedades proliferativas tales como el cancer, hiperplasia, hipertrofia cardiaca, enfermedades autoinmune, trastornos fungicos, artritis, rechazo a imjertos, entre otras.

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008502721A (ja) * 2004-05-21 2008-01-31 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 分裂キネシンインヒビターとしての置換キノリン誘導体
JP2008503501A (ja) * 2004-06-18 2008-02-07 カイロン コーポレイション 癌を治療するためのキネシンスピンドルタンパク質（ｋｓｐ）阻害剤としてのｎ−（１−（１−ベンジル−４−フェニル−１ｈ−イミダゾール−２−イル）−２，２−ジメチルプロピル）ベンズアミド誘導体および関連化合物
JP2008517057A (ja) * 2004-10-19 2008-05-22 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド インドールおよびベンゾイミダゾール誘導体
JP2008527038A (ja) * 2005-01-19 2008-07-24 メルク エンド カムパニー インコーポレーテッド 有糸分裂キネシン阻害剤
JP2008535839A (ja) * 2005-04-07 2008-09-04 メルク エンド カムパニー インコーポレーテッド 有糸分裂キネシン阻害剤
JP2009542658A (ja) * 2006-06-27 2009-12-03 ザ プロクター アンド ギャンブル カンパニー ヒトプロテインチロシンホスファターゼβ阻害剤および使用法
JP2010509365A (ja) * 2006-11-13 2010-03-25 ノバルティス アーゲー Ｋｓｐ阻害剤としての置換ピラゾールおよびトリアゾール化合物
WO2009077448A1 (en) * 2007-12-14 2009-06-25 Novartis Ag Kinesin inhibitors as cancer therapeutics
JP2013523867A (ja) * 2010-04-15 2013-06-17 ノバルティス アーゲー Ｋｓｐ阻害剤としてのトリアゾール化合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013523867A (ja) * 2010-04-15 2013-06-17 ノバルティス アーゲー Ｋｓｐ阻害剤としてのトリアゾール化合物

Also Published As

Publication number Publication date
EP2558452A2 (en) 2013-02-20
US20130224186A1 (en) 2013-08-29
CN103153970A (zh) 2013-06-12
WO2011128388A3 (en) 2013-03-14
US8748626B2 (en) 2014-06-10
WO2011128388A2 (en) 2011-10-20

Similar Documents

Publication Publication Date Title
US7820646B2 (en) Cyclized derivatives as Eg-5 inhibitors
RU2385867C2 (ru) Замещенные производные хинолина как ингибиторы митотического кинезина
JP2008517057A (ja) インドールおよびベンゾイミダゾール誘導体
JP5264755B2 (ja) Ｋｓｐ阻害剤としての置換ピラゾールおよびトリアゾール化合物
JP2013525290A (ja) Ｋｓｐ阻害剤としてのオキサゾールおよびチアゾール化合物
WO2020062883A1 (zh) 基于知母菝契皂苷元结构的衍生物、药物组合物及其应用
US7626040B2 (en) Substituted imidazole compounds as KSP inhibitors
JP2013523867A (ja) Ｋｓｐ阻害剤としてのトリアゾール化合物
EA021067B1 (ru) Производные бензотиазолона
MX2008001411A (en) Substituted imidazole compounds as ksp inhibitors
KR20070023689A (ko) 유사분열 키네신 억제제로서의 치환 퀴놀린 유도체

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140306

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140306

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20140815

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20140902

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150127

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150129

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150707